Trillium Therapeutics’ TTI-621 Acquires FDA Clearance

The FDA has given Trillium Therapeutics clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI-621, to treat solid tumors and mycosis fungoides.

TTI-621 will be delivered by intratumoral injection in patients with relapsed and refractory, percutaneously accessible cancers.

This drug is designed as a checkpoint inhibitor of the innate immune system.